With a goal to continuously improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference. Taking place from June 9-11 in Manchester, England, the event is expected to attract many of the world’s most prominent ocular health experts.

Three-Year Myopia Control Efficacy of DOT™ Spectacle Lenses in Young Children (Laughton D., et al.) centers on a sub-group six-to-seven-year-olds who participated in the company’s pivotal CYPRESS clinical trial, with investigators noting expectations of highly progressive myopia and a paucity of efficacy data for this age group.  After three years, myopia progression among these young children was limited to <1.00 D in 60% of Diffusion Optics Technology 0.2 spectacle lens wearers compared to 21% of control lens wearers. This data—shared for the first time in Manchester—further supports previously announced safety and efficacy outcomes.

Reliability of Quality of Vision Questionnaire Results from Children (McParland M., et al.) assessed pediatric application of the Quality of Vision (QoV) questionnaire, which is more commonly used for adult refractive surgery and intraocular lens research. Investigators abbreviated the standard QoV instrument to focus on glare, hazy vision, and halos, then analyzed responses from CYPRESS clinical trial participants and from their parents/guardians across three years. The greater consistency of within-child agreement compared to parent-child response agreement suggests that parents may under-report their children’s experiences, while also affirming that children as young as age six can share meaningful QoV-derived insights to help inform clinical decisions.

Peripheral Visual Function with DOT Spectacle Lenses for Myopia Control (Aboualizadeh E., et al.) debuts at the BCLA meeting, tapping into the rich CYPRESS data set to review long-term changes in peripheral visual acuity (VA) after three years of Diffusion Optics Technology™ spectacle lens wear. Compared to the baseline, peripheral VA improved or remained stable, with no significant differences between the DOT and standard single-vision groups.

SightGlass Vision has also organized one of eight prominent peer review track sessions at the conference on Saturday: How Do Myopia Management Therapies Work and Does It Matter?, led by global myopia experts Prof. Nicola Logan and Prof. James Wolffsohn. Anticipated high demand for the session requires pre-booking from attendees.

“We are deeply committed to advancing myopia control, evidenced by our presentations at the BCLA Conference plus recent efficacy, safety, and visual performance data reporting at ARVO in North America and COOC in China. Eye care professionals can confidently prescribe Diffusion Optics Technology™ spectacle lenses, knowing the outcomes are supported by extensive science,” said Andrew Sedgwick, CEO of SightGlass Vision.

Spectacle lenses with SightGlass Vision™ Diffusion Optics Technology™ use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent-protected technology with clinically proven efficacy[1],[2],[3] made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.

For more information, visit SightGlassVision.com.


About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.


SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.


Media Contact

Mike McDougall, APR, Fellow PRSA, FAAO

McDougall Communications for SightGlass Vision

+1-585-545-1815 or mike@mcdougallpr.com